New appointment at Presidio Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Presidio Pharmaceuticals (US) has appointed Eric Ruby vice-president of regulatory affairs. He has more than 20 years' experience in regulatory strategy, data review and communications with regulatory agencies, having previously served as senior director or regulatory affairs at Alnylam Pharmaceuticals, where he was responsible for regulatory filings to support clinical trials in the US and Europe. Before he started working in the pharmaceutical industry, Mr Ruby held positions at the US FDA, first as a chemistry reviewer and subsequently as a manager for drug metabolism and pharmacokinetic studies.